ArticleCancer immunology, immunotherapy : CII2016
Optimized magnitude of cryosurgery facilitating anti-tumor immunoreaction in a mouse model of Lewis lung cancer.
Article in Cancer immunology, immunotherapy : CII, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial.Nature communications · 2024Trial
- Cryoablation combined with immunotherapy: new strategies and progress in the treatment of tumors.Frontiers in oncology · 2026Review
- Immunomodulatory impacts of thermal and pulsed field ablation therapy on hepatocellular carcinoma associated with viral hepatitis.Radiologie (Heidelberg, Germany) · 2025Review
- A Phase I Dose-Escalation Clinical Trial of Bronchoscopic Cryoimmunotherapy in Advanced-Stage NSCLC.JTO clinical and research reports · 2025Article
- Modern cancer therapy: cryoablation meets immune checkpoint blockade.Frontiers in oncology · 2024Review
- Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends.International journal of molecular sciences · 2023Review
- Interventional Radiology in the Treatment of Pancreatic Adenocarcinoma: Present and Future Perspectives.Life (Basel, Switzerland) · 2023Review
- Synergetic Thermal Therapy for Cancer: State-of-the-Art and the Future.Bioengineering (Basel, Switzerland) · 2022Review
- Tumor-Specific Immunoenhancing Effects after Local Cryoablation for Metastatic Bone Tumor in a Mouse Model.International journal of molecular sciences · 2022Article
- Untargeted metabolomics profiling in a mouse model of lung cancer treated with thermal ablation.Bioengineered · 2022Article
- An In Vitro Investigation into Cryoablation and Adjunctive Cryoablation/Chemotherapy Combination Therapy for the Treatment of Pancreatic Cancer Using the PANC-1 Cell Line.Biomedicines · 2022Article
- The Abscopal Effect in the Era of Checkpoint Inhibitors.International journal of molecular sciences · 2021Review
- Abscopal Effect of Frozen Autograft Reconstruction Combined with an Immune Checkpoint Inhibitor Analyzed Using a Metastatic Bone Tumor Model.International journal of molecular sciences · 2021Article
- Immune modulation resulting from MR-guided high intensity focused ultrasound in a model of murine breast cancer.Scientific reports · 2021Article
- Local Destruction of Tumors and Systemic Immune Effects.Frontiers in oncology · 2021Review
- Changes in and effects of Kupffer cells on residual tumor after cryoablation in rabbit hepatic VX2 tumor.International journal of clinical and experimental pathology · 2021Article
- Cryoablation for advanced non-small cell lung cancer: a protocol for a systematic review.BMJ open · 2020Article
- Cryoablation and immunotherapy: an overview of evidence on its synergy.Insights into imaging · 2019Review
- Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors.Frontiers in immunology · 2019Review
- Inhibition effects of Yuxiao San combined with cisplatin on transplanted tumor growths via upregulation of nm-23 and downregulation of K-ras in Lewis lung cancer mice.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCryosurgery has reemerged as a less invasive local treatment with possible immune-regulatory effects. However, the optimal magnitude of cryosurgery for achieving immune-regulatory responses at abscopal tumor sites remains unclear. We aimed to investigate appropriate magnitude of cryosurgery for this goal using a mouse model.
methodsC57BL/6J mice were inoculated with Lewis lung carcinoma cells or B16 melanoma cells in bilateral flanks. The left-sided tumor was cryoablated with repeated freeze/thaw cycles either once, twice, or thrice. The peritumoral injections of LPS were performed. Abscopal tumor volumes were measured, immunohistochemistry was performed for CD4, CD8, Foxp3, and Ki-67, and proinflammatory cytokines were measured in lavage fluid of cryoablated tumor.
resultsThe growth rate of the abscopal tumor was slowest in the Cryosurgery ×2 group among the five experimental groups. The proportions of CD4(+) T cells and CD8(+) T cells in the abscopal tumor were also significantly higher in the Cryosurgery ×2 group. The levels of IL-1β, IL-2, IL-6, IL-12β, IFN-γ, and TNF-α in the peritumoral lavage fluid in Cryosurgery ×2 + LPS group were significantly increased compared with the other groups.
conclusionsThis study suggested that achievement of approximately 73 % damaged area in the cryoablated tumor by two cycles of cryosurgery generates the most favorable immune-regulatory response for abscopal tumors via activation of anti-tumor immune cells as well as increased secretion of proinflammatory cytokines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.